Could vaccine committee give CytoDyn a leg up on approval process? Below is a roster of the vaccine advisory committee of the FDA who send their recommendations to the CBER of FDA in the last step before sending their review to the FDA commish Hahn. Note that the chair of this committee is Dr. Sahly, an associate professor from Baylor University, where our current CD12 trials are being conducted. Could his first-hand knowledge of how our trial worked out help in conveying the results down the line and up the ladder in the approval process? It's only conjecture on my part, but maybe, just maybe we might get a break with a connection able to break the logjam and get us into the limelight. Here's the roster:

https://www.fda.gov/advisory-committees/vacci...-committee